Show simple item record

dc.contributor.authorLogue, C.
dc.contributor.authorPugh, Julia
dc.contributor.authorFoden, Philip
dc.contributor.authorMahmood, Reem D
dc.contributor.authorMorgan, Robert David
dc.contributor.authorMitchell, Claire L
dc.contributor.authorHasan, Jurjees
dc.contributor.authorClamp, Andrew R
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2021-07-28T12:41:43Z
dc.date.available2021-07-28T12:41:43Z
dc.date.issued2021en
dc.identifier.citationLogue CA, Pugh J, Jayson G. Psychosexual morbidity in women with ovarian cancer. 2020;- 30(- 12):- 1989.en
dc.identifier.urihttp://hdl.handle.net/10541/624178
dc.description.abstractObjective Psychosexual morbidity (PSM) is known to be present in up to 75% of women with ovarian cancer (OC). 15–20% of patients with high-grade serous OC have a germline BRCA1/2 mutation (gBRCAm-OC). Given their younger age, breast cancer risk and increased prevalence of surgically induced menopause, we hypothesised that women with gBRCAm-OC would experience more profound PSM. Design We evaluated PSM in two cohorts of patients with OC; women with gBRCAm-OC and with wild type or unknown BRCA status (gBRCAwt-OC). Women with highgrade serous OC were invited to participate in this singlecentre, observational study and asked to complete the Female Sexual Function Index (FSFI) questionnaire, alongside demographic and prior treatment details. The FSFI is a 19-item self-report measure assessing six domains of sexual functioning (desire, arousal, lubrication, orgasm, satisfaction and pain), creating a maximum total score of 36. Methods Descriptive and statistical analysis were carried out on Microsoft Excel and GraphPad Prism 9. FSFI scores below the conventional threshold of 26.55 are interpreted to suggest sexual dysfunction. Results Between August 2019 and March 2020, 103 women with OC were sequentially approached to anonymously participate via a gynaecological medical oncology clinic or by telephone to participate by post. Over half of those who agreed returned questionnaires; gBRCAm-OC (n = 26) and gBRCAwt-OC (n = 29). Women with gBRCAm-OC scored higher on the FSFI questionnaire compared to gBRCAwt-OC, suggesting better sexual function; particularly in women under 60 years (15.1 versus 2.7, P = 0.070). Women with gBRCAm-OC were more interested in face-to-face services (P = 0.018**), were significantly younger than women with gBRCAwt-OC (median age range 51-60 years versus 61-70 years, P = 0.010**), reported greater arousal and satisfaction, and were more likely to have undergone surgical menopause (57% versus 27%, P = 0.097) and previous breast surgery (53% versus 22%, P = 0.132). Overall, 91% of women did not recall being asked about PSM and 71% of women with gBRCAm-OC (versus 44% of gBRCAwt-OC, P = 0.076) felt that the service did not address their needs. Discussion Despite national recommendations, PSM remains unaddressed in patients with OC. Women with gBRCAm-OC appear to have more risk factors for PSM: younger age, surgical menopause and previous breast surgery, report higher arousal and satisfaction and are more interested in face-to-face support. The FSFI is unsuitable for sexually inactive women and could not quantify PSM overall yet has no reasonable replacement. Further work to improve PSM recognition and questionnaires to explore the prevalence of PSM in the gBRCAm-OC population is recommended.en
dc.language.isoenen
dc.titlePsychosexual dysfunction in women with ovarian cancer; evaluation by BRCA-gene mutational statusen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Manchester University NHS Foundation Trust, Manchesteren
dc.identifier.journalBjog-an International Journal of Obstetrics and Gynaecologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record